Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data

被引：0
|
作者：
Ash Bullement
Samuel Thomas McMordie
Anthony James Hatswell
Nanxin Li
Koo Wilson
机构：
[1] Delta Hat,
[2] University College London,undefined
[3] Bioverativ,undefined
[4] a Sanofi Company,undefined
[5] Swedish Orphan Biovitrum AB (publ),undefined
来源：
PharmacoEconomics - Open | 2020年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：133 / 142
页数：9
相关论文
共 50 条
  • [41] Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis
    Carcao, Manuel
    Shapiro, Amy
    Hwang, Nina
    Pipe, Steven
    Ahuja, Sanjay
    Lieuw, Ken
    Staber, Janice M.
    Belletrutti, Mark
    Sun, Haowei Linda
    Ding, Hilda
    Wang, Michael
    Price, Victoria
    Steele, MacGregor
    Tsao, Elisa
    Feng, Jing
    Al-Khateeb, Zahra
    Dumont, Jennifer
    Jain, Nisha
    HAEMOPHILIA, 2021, 27 (01) : 19 - 25
  • [42] ECONOMIC EVALUATION OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) FOR IMMUNE TOLERANCE INDUCTION (ITI) IN PATIENTS WITH HEMOPHILIA A WHO DEVELOP INHIBITORS UNDER THE BRAZILIAN UNIFIED HEALTH SYSTEM (SUS) PERSPECTIVE
    Teich, V
    Li, N.
    Brito, K.
    Krishnan, S.
    Su, J.
    VALUE IN HEALTH, 2018, 21 : S251 - S251
  • [43] Longitudinal analysis of von Willebrand factor (VWF) levels in the phase 3 a-long study of recombinant factor VIII FC fusion protein (RFVIIIFC) in subjects with hemophilia a demonstrates different magnitudes of temporal variability
    Lillicrap, D.
    Kulkarni, R.
    Li, S.
    Tsao, E.
    Long, A.
    Pierce, G. F.
    Dumont, J. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 753 - 753
  • [44] COST-EFFECTIVENESS ANALYSIS OF TUMOR TREATING FIELDS IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA BASED ON REAL-WORLD DATA
    Xiang, Y.
    Xu, Z.
    Zhou, S.
    Liu, S.
    Chen, Y.
    VALUE IN HEALTH, 2023, 26 (06) : S76 - S76
  • [45] Long-term efficacy and safety of prophylactic treatment with recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with severe haemophilia A: Final longitudinal analysis of A-LONG/kids A-LONG and ASPIRE
    Konkle, B.
    Young, G.
    Liesner, R.
    Mahlangu, J.
    Brown, S. A.
    Nolan, B.
    Tripkovic, N.
    Feng, J.
    Barnowski, C.
    HAEMOPHILIA, 2019, 25 : 55 - 55
  • [46] INDIRECT COMPARISON OF THE EFFICACY OF RECOMBINANT FACTOR IX FC FUSION PROTEIN AND OTHER FACTOR IX PRODUCTS FOR PROPHYLAXIS: SIMULATING THE EFFECT OF COMPLIANCE ON REAL-WORLD EFFECTIVENESS
    Iorio, A.
    Krishnan, S.
    Huynh, L.
    Karner, P.
    Duh, M. S.
    Yermakov, S.
    VALUE IN HEALTH, 2014, 17 (03) : A230 - A230
  • [47] Dosing intervals and bleeding rates before and following treatment with recombinant factor VIII Fc fusion protein in patients with severe haemophilia A: experience from the A-LONG clinical study
    Oldenburg, J.
    Shapiro, A.
    Ragni, M. V.
    Kulkarni, R.
    Kulke, S.
    Potts, J.
    Neelakantan, S.
    Nestorov, I.
    Dumont, J. A.
    Jiang, H.
    Brennan, A.
    Pierce, G. F.
    HAEMOPHILIA, 2014, 20 : 60 - 61
  • [48] SEQUENTIAL TREATMENT REGIMENS FOR ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A COST-EFFECTIVENESS ANALYSIS INCLUDING EXPERIENCE FROM REAL-WORLD DATA
    Rochau, U.
    Vukicevic, D.
    Angerer, S.
    Schaffner, M.
    Rushaj, Qerimi, V
    Conrads-Frank, A.
    Jahn, B.
    Hackl, W. O.
    Ammenwerth, E.
    Stummer, H.
    Garrison, L. P.
    Weger, R.
    Willenbacher, E.
    Willenbacher, W.
    Siebert, U.
    VALUE IN HEALTH, 2019, 22 : S467 - S467
  • [49] Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years
    Shapiro, Amy
    Chaudhury, Ateefa
    Wang, Michael
    Escobar, Miguel
    Tsao, Elisa
    Barnowski, Christopher
    Feng, Jing
    Jain, Nisha
    Quon, Doris V.
    HAEMOPHILIA, 2020, 26 (06) : 975 - 983
  • [50] Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data
    Deininger, Kimberly M.
    Anderson, Heather D.
    Patrinos, George P.
    Mitropoulou, Christina
    Aquilante, Christina L.
    PHARMACOGENOMICS JOURNAL, 2024, 24 (03):
12345